Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

@article{Minckwitz2011TrastuzumabBP,
  title={Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.},
  author={Gunter von Minckwitz and Kathrin Schwedler and Marcus Schmidt and J. M. Barinoff and Christoph Mundhenke and Tanja {\vC}ufer and Eduard Maartense and Felix E. de Jongh and Klaus Heinrich Baumann and Joachim Bischoff and Nadia Harbeck and Hans Joachim L{\"u}ck and Nicola{\`i} Maass and Christoph Zielinski and Michael Andersson and Robert C. Stein and Valentina Nekljudova and Sibylle Loibl},
  journal={European journal of cancer},
  year={2011},
  volume={47 15},
  pages={2273-81}
}
BACKGROUND Continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabine (X) alone in women with HER2-positive breast cancer progressing during trastuzumab treatment. Here, we report the final analysis on overall survival. PATIENTS AND METHODS Patients with HER2-positive, advanced breast cancer who progressed during treatment with trastuzumab with or without 1st-line metastatic chemotherapy were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Similar Papers

Loading similar papers…